Kirk Kerkorian School of Medicine at UNLV Hematology and Medical Oncology

Topics

• Cancer Immunotherapy and Biomarkers 16
• Renal cell carcinoma treatment 14
• Cutaneous Melanoma Detection and Management 13
• Innovations in Medical Education 13
• Brain Metastases and Treatment 10
• Diversity and Career in Medicine 7
• Melanoma and MAPK Pathways 7
• Nitric Oxide and Endothelin Effects 7
• Chronic Lymphocytic Leukemia Research 6
• Disaster Response and Management 6
• Lung Cancer Treatments and Mutations 6
• Pancreatic and Hepatic Oncology Research 6

Most cited

1. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

   Nature medicine · 2025 · 94 citations · Fadi Braiteh

2. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

   Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 74 citations · Fadi Braiteh

3. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.

   Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 25 citations · Wolfram Samlowski

4. Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series.

   The oncologist · 2021 · 23 citations · Wolfram Samlowski

5. Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.

   Oncotarget · 2023 · 12 citations · Wolfram Samlowski

6. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.

   Clinical cancer research : an official journal of the American Association for Cancer Research · 2022 · 26 citations · Fadi Braiteh

7. Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data.

   Biomedicines · 2022 · 20 citations · Wolfram Samlowski

8. Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma.

   Cancers · 2023 · 10 citations · Wolfram Samlowski